Inspiration Biopharmaceuticals appoints former Genzyme exec as CEO

BY Alaric DeArment

LAGUNA NIGUEL, Calif. — A drug maker that focuses on treatments for hemophilia has named a new CEO.

Inspiration Biopharmaceuticals announced Tuesday the appointment of John Butler as chief executive officer. Butler replaces Michael Griffith, who is taking the role of chief scientific officer while retaining the title of president.

Butler previously worked at Genzyme, which French drug maker Sanofi acquired in April. There, he served as president of the company’s rare genetic diseases business and also led its renal, endocrinology and cardiovascular businesses. Before that, he worked in sales and marketing for Amgen and Hoffmann-La Roche.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.


Leave a Reply

No comments found



Under fire

BY Rob Eder

Under fire. That is the best way to describe the current state of the proposed $29 billion mega-merger of two of the nation’s three largest pharmacy benefit managers, and the fierce resistance it is drawing from pharmacy and consumer groups. If the plan is approved, Express Scripts will emerge as a PBM giant with a network covering some 135 million members.

Appearing before a Sept. 20 House Judiciary Subcommittee hearing called to explore potential antitrust issues related to the proposed merger, Express Scripts and Medco executives made their case. The deal, said Express Scripts chairman and CEO George Paz, “will help make prescription drugs more affordable for seniors, people with disabilities and working families. It will also help small businesses and large employers … to rein in their medical costs.”

Medco chairman and CEO David Snow told the House panel that PBM clients still would have “plenty of competitive choices post-merger, and the combined Express Scripts and Medco will be fully subject to the competitive pressures that will ensure value-based pricing and service.”

In fact, according to Express Scripts spokesman Brian Henry, the PBM sector “is a very dynamic, competitive marketplace. There [are more than] 40 PBMs in the marketplace, and 10 different companies servicing the Fortune 50 companies,” he told Drug Store News.

However, the true competitive picture appears far less robust. According to research conducted by Barclay’s Capital analysts, once you carve out the new ESI-Medco’s 41% share of total U.S. prescriptions filled, Caremark’s share (about 28%), and OptumRx (about 14%), that leaves seven  companies fighting over about 15% of the pie. Factor out Catalyst Health and Prime Therapeutics — each about 5% of the market — and that’s five companies left to fight over the remaining 5% or so.
Then there’s the grip the new company would have on the mail-order business (about 60%), and more so, the rapidly growing and highly costly specialty pharmacy market (more than 50%).

Expressing “grave concerns,” Dennis Wiesner, senior director of privacy, pharmacy and government affairs at H-E-B — who spoke on behalf of the National Association of Chain Drug Stores during the Sept. 20 hearing — told House members that the deal, if approved, “would be a tipping point in PBM consolidation, harming patients, as well as government and private health plans and employers.”

In particular, Wiesner drew lawmakers’ attention to what he called the “opaque manner” under which PBMs operate. “There is no proof that [PBMs] pass along their purported savings to health plans, employers or consumers. In fact, the PBM industry has been fraught with allegations of extensive deceptive and fraudulent practices,” such as accepting manufacturer rebates for placing higher-priced medications on drug formularies, switching customers to those medicines and benefiting from both, he said.

Amplifying Wiesner’s message was Pennsylvania-based independent pharmacist Joe Lech. “ESI and Medco say that this merger will drive out so-called ‘waste’ in the healthcare system,” said Lech, who spoke on behalf of the National Community Pharmacists Association. “Frankly, these are just code words for squeezing my pharmacy reimbursement as far down as they can and trying to shift as many of my patients as they can to their own mail-order facilities,” he added. “My pharmacy has no leverage. … In my pharmacy, this merged company will pay for more than half of the prescriptions filled.”

Lech also attacked the two PBMs on generic utilization — which “everyone knows is the fastest way to reduce drug costs,” he said. “The generic rate at the ESI mail facility is 60%. It is 62% at the Medco facility. By contrast, community pharmacies dispense generics on average 72% of the time,” he said.

Meanwhile, both sides tried to amplify the message for all Beltway influentials to hear and see during the week of the Sept. 20 hearing. A NACDS-sponsored ad (which can be heard at played on radios throughout the Capitol. And ESI and Medco ran print ads that appeared in important D.C. papers like The Hill and Politico that week. “We protect consumers from the rising cost of prescription drugs,” the ESI-Medco ad promises.

Yet, for all of that “protection,” you can say that five of the biggest consumer interest groups in America just aren’t feeling it — Consumers Union, Consumer Federation of America, the National Consumers League, U.S. PIRG and the National Legislative Association on Prescription Drug Prices have all come out against the merger.

Other groups also have expressed opposition, including the National Coordinating Committee for Multiemployer Plans, the Independent Specialty Pharmacy Coalition, the Food Marketing Institute and the California Pharmacists Association. Representing some of those groups is David Balto, a Washington-based attorney and former FTC policy director.

“The mere fact that the FTC has issued a second request, that they’re conducting dozens of interviews and that they’ve been joined by numerous state attorneys general, shows that the law enforcers believe that this merger is not business as usual, and it’s not going to get a quick-glance approach,” Balto told DSN.

Although the deal could impact how pharmaceuticals reach the market, the industry group Pharmaceutical Research and Manufacturers of America has not taken a position on the merger. Still, even without PhRMA piling on, the arrows are flying from seemingly every direction.

According to ESI’s Henry, both companies still are as confident as ever that the deal will close, and are sticking with the original second quarter 2012 timeline.


Leave a Reply

No comments found



Q&A: Neighborhood marketing


Drug Store News caught up with J.D. Schulman, CEO of Vesta Retail Networks, to talk about the company’s retailer-exclusive neighborhood marketing networks — a program that reaches affluent shoppers in a unique way by creating advertising opportunities out of the hangers used for dry cleaning. It’s not only an out-of-the-box approach to delivering targeted messaging, but it’s green, too — the “eco-hangers” and attached cardboard advertisements are both created out of 100%-recycled material, and the finished hanger is recyclable to boot.

DSN: What does VRN do for retailers?

J.D. Schulman: Our mission is to drive affluent customers to our retail customers via the affluent shopper networks we operate. Today, securing a scalable, affordable and affluent shopper network is critically important for retailers looking for more customers, new customers and bigger market baskets. … We work exclusively with leading retailers, which license channel-exclusive affluent shopper networks. No other company provides this localized-yet-national approach to reaching affluent customers necessary to drive sales increases in this current challenging environment.

DSN: How is this media vehicle more influential than other more traditional outlets?

Schulman: These leading retailers are licensing our affluent shopper networks to bring their suppliers an extended way to reach the coveted affluent households within the correct drive times around their stores. Our patented in-home billboards [are] hyper-efficient; [they] reach shopper households around our retail partners with nearly 100% view rates and 100% open rates — that’s unlike any other media vehicle that retailers have in their arsenal.

DSN: You’ve set up the Walgreens Neighborhood Marketing Network. How does that work exactly?

Schulman: We have 35,000 dry cleaners in our network that distribute our in-home billboards on our patented eco-hanger product. But you can’t advertise through all 35,000 dry cleaners. If you think of the Walgreens network and their 7,500-plus stores, that’s 7,500-plus neighborhoods. In those neighborhoods, there are four or five dry cleaners around each store. Those dry cleaners are selected to receive these in-home billboards. …

On average, the Walgreens Neighborhood Marketing Network has a household income [demographic] right around $100,000. [This program] reaches the 28% of households that do dry cleaning. Just by the very nature of the program, this is reaching more brand-centric consumers who have the pocketbooks to make purchase decisions not based on price, but based on preference.

DSN: Is this a one-size-fits-all program, or can suppliers manipulate and customize what’s included in the media?

Schulman: An individual supplier, for Walgreens as an example, can find out more about the program on a custom Web page at There [the supplier] can find out rates, dates, that kind of thing. Not only do the suppliers have the chance for in-home display via the billboards, but also couponing, sampling, promotion and QR code distribution — a number of ways in one single program to activate these affluent shoppers.

For the full audio Q&A, click here.


Leave a Reply

No comments found